Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

